论文信息 - Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial - 字舞流文

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees | D. Watson-Jones | B. Lowe | B. Greenwood | D. Heerwegh | H. Larson | J. Foster | D. Ishola | G. Deen | E. Smout | K. Gallagher | D. Manno | V. Bockstal | F. Baiden | Thomas Mooney | D. Kowuor | M. Afolabi | Benoît Callendret | Auguste Gaddah | B. Leigh | M. Douoguih | Mohamed Samai | Babajide Keshinro | N. Goldstein | K. Luhn | Cynthia Robinson | M. Leyssen | B. Rogers | Kwabena Owusu-Kyei | Alimamy Serry-Bangura | I. Swaray | Brian Köhn | Godfrey T Otieno | Morrison Jusu | C. Robinson | Dirk Heerwegh | B. Callendret | Maarten Leyssen | G. T. Otieno

[1] S. Lees,et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial , 2021, The Lancet. Infectious diseases.

[2] H. Schuitemaker,et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate , 2020, NPJ vaccines.

[3] Y. Lévy,et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. , 2020, The Lancet. Infectious diseases.

[4] R. Das,et al. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults , 2019, The Journal of infectious diseases.

[5] S. Kapiga,et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania , 2019, The Journal of infectious diseases.

[6] O. Anzala,et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya , 2019, The Journal of infectious diseases.

[7] D. Watson-Jones,et al. Prevention of Ebola virus disease through vaccination: where we are in 2018 , 2018, The Lancet.

[8] D. Watson-Jones,et al. EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country , 2018, Clinical trials.

[9] S. Lees,et al. "We are the heroes because we are ready to die for this country": Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial. , 2018, Social science & medicine.

[10] H. Schuitemaker,et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates , 2018, PloS one.

[11] A. Saxena,et al. Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials , 2017, Reproductive Health.

[12] A. MacNeil,et al. Considerations for use of Ebola vaccine during an emergency response. , 2017, Vaccine.

[13] M. Voysey,et al. Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year , 2017, JAMA.

[14] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.

[15] S. Lees,et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone , 2016, BMC Public Health.

[16] H. Schuitemaker,et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. , 2016, JAMA.